Vertex Pharmaceuticals Files 8-K

Ticker: VRTX · Form: 8-K · Filed: May 20, 2024 · CIK: 875320

Sentiment: neutral

Topics: corporate-filing, sec-filing, financial-reporting

Related Tickers: VRTX

TL;DR

Vertex Pharma filed an 8-K on 5/20. Standard corporate update.

AI Summary

Vertex Pharmaceuticals Incorporated filed an 8-K on May 20, 2024, to report other events and financial statements. The filing details the company's principal executive offices located at 50 Northern Avenue, Boston, Massachusetts, 02210, and its primary business phone number as (617) 341-6100. The company is incorporated in Massachusetts and operates within the Pharmaceutical Preparations industry.

Why It Matters

This filing serves as an official record of Vertex Pharmaceuticals' corporate activities and financial reporting, providing transparency to investors and the public.

Risk Assessment

Risk Level: low — This is a routine corporate filing with no new material information that would inherently increase risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of May 20, 2024.

Where are Vertex Pharmaceuticals' principal executive offices located?

Vertex Pharmaceuticals' principal executive offices are located at 50 Northern Avenue, Boston, Massachusetts, 02210.

What is the filing date of this report?

The filing date of this report is May 20, 2024.

What is the company's telephone number?

The registrant's telephone number, including area code, is (617) 341-6100.

In which state is Vertex Pharmaceuticals incorporated?

Vertex Pharmaceuticals Incorporated is incorporated in Massachusetts.

Filing Stats: 1,034 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2024-05-20 08:36:00

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: May 20, 2024 /s/ Jonathan Biller Jonathan Biller Executive Vice President, Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing